Lysosomal Storage Diseases

• Definition: a family of inherited defects of lysosomal catabolism in which a missing or non-functional acid hydrolase (or its activator protein, transporter, or trafficking machinery) allows an undegraded macromolecule to accumulate inside the lysosome, converting a recycling organelle into a toxic storage compartment.
• Why they matter clinically: they are the prototype of progressive regression — the child achieves milestones, then loses them. Recognizing the pattern (regression plus organomegaly, dysmorphism, or a marrow/eye finding) is what separates a treatable enzyme deficiency from an untreatable primary neurodegeneration, and several now have disease-modifying therapy that works only if started early.
• Substrate classes tested: sphingolipidoses (Gaucher, Niemann-Pick, Tay-Sachs, Krabbe, metachromatic leukodystrophy, Fabry), mucopolysaccharidoses (Hurler, Hunter), oligosaccharidoses, and the glycogen-storing exception, Pompe.

Epidemiology worth recalling

• Individually rare, collectively not: each disorder is orphan-level, but as a group lysosomal storage diseases are among the more frequently encountered inborn errors of metabolism in pediatrics.
• Gaucher disease is the most common lysosomal storage disease overall; Fabry disease is among the most common in adults because attenuated variants survive to adulthood.
• Founder effects are the classic exam hook: Tay-Sachs, Gaucher type 1, and Niemann-Pick type A are all enriched in the Ashkenazi Jewish population, with Tay-Sachs carrier frequency in that group on the order of 1 in 27. ACOG and the American College of Medical Genetics and Genomics recommend offering carrier screening for Tay-Sachs disease (with expanded panels including Gaucher and Niemann-Pick A available) to individuals of Ashkenazi Jewish ancestry, and ACOG endorses pan-ethnic screening options as well.
• Newborn screening: Pompe disease and mucopolysaccharidosis type I are on the federal Recommended Uniform Screening Panel, so an increasing number of cases in the U.S. are now detected presymptomatically rather than after regression begins.

Step 1 — Building the lysosome (the trafficking step examiners love)

• Synthesis and tagging: acid hydrolases are translated into the rough ER, N-glycosylated, then in the *cis*-Golgi receive mannose-6-phosphate (M6P) via GlcNAc-1-phosphotransferase.
• Sorting: M6P receptors in the *trans*-Golgi bind the tag and divert enzymes to the late endosome. Loss of the phosphotransferase means enzymes are secreted into plasma instead of delivered — the mechanism of I-cell disease (mucolipidosis II).
• Activation: the vacuolar H⁺-ATPase acidifies the lumen to roughly pH 5, the optimum for acid hydrolases; this pH dependence is why they are relatively inert if they leak into neutral cytosol.

Step 2 — Sequential, obligate degradation

• Substrates are stripped one residue at a time, so any single missing enzyme halts the entire line and the immediately upstream metabolite accumulates. There is no bypass pathway — this is why phenotype maps so tightly to enzyme identity.
• Sphingolipid ladder (all funnel toward ceramide): sphingomyelin → sphingomyelinase → ceramide; glucocerebroside → glucocerebrosidase → ceramide; galactocerebroside → galactocerebrosidase; sulfatide → arylsulfatase A; GM2 ganglioside → hexosaminidase A → GM3; globotriaosylceramide (Gb3) → α-galactosidase A.
• Cofactor requirement: several hydrolases need saposins or the GM2 activator protein; deficiency of the activator alone reproduces the disease with a normal enzyme assay.
• Glycosaminoglycans need alternating sulfatases and exoglycosidases (α-L-iduronidase, iduronate-2-sulfatase), which is why mucopolysaccharidoses share coarse facies and dysostosis across subtypes.

Rate-limiting and regulatory points

• The deficient hydrolase itself is the rate-limiting step; disease severity tracks residual enzyme activity, not genotype per se — near-zero activity gives infantile neuronopathic disease, partial activity gives adult-onset visceral disease.
• Lysosomal biogenesis is transcriptionally driven by TFEB, which is held inactive by mTORC1 on the lysosomal surface; storage stress activates this axis, producing the engorged, enzyme-overexpressing lysosomes seen histologically.
• Neurons are disproportionately vulnerable because they are post-mitotic and cannot dilute stored material by division.

Trafficking failure

• I-cell disease (mucolipidosis II): absent M6P tagging → hydrolases secreted, so plasma acid hydrolase levels are elevated while cells starve. Coarse facies, gingival hyperplasia, corneal clouding, restricted joints, death in early childhood.

Sphingolipidoses — mapped to the blocked step

• Sphingomyelinase (Niemann-Pick A/B): foam cells laden with sphingomyelin; massive hepatosplenomegaly, and in type A a cherry-red macula with regression. Niemann-Pick C is different in mechanism — a cholesterol trafficking protein defect (NPC1) presenting with vertical supranuclear gaze palsy and ataxia.
• Glucocerebrosidase (Gaucher): macrophages become Gaucher cells with "crumpled tissue paper" cytoplasm; pancytopenia, bone crises, avascular necrosis of the femoral head.
• Hexosaminidase A (Tay-Sachs): GM2 in neurons → cherry-red macula, hyperreflexia, exaggerated startle, macrocephaly — with no hepatosplenomegaly. Sandhoff adds hexosaminidase B loss plus organomegaly.
• Galactocerebrosidase (Krabbe): globoid cells, peripheral neuropathy, optic atrophy, irritability with unexplained fevers.
• Arylsulfatase A (metachromatic leukodystrophy): central and peripheral demyelination — ataxia, gait failure, then dementia.
• α-Galactosidase A (Fabry): X-linked; Gb3 deposits in endothelium and podocytes → acroparesthesias, hypohidrosis, angiokeratomas in a bathing-trunk distribution, corneal verticillata, proteinuric renal failure, and cryptogenic stroke in a young adult.

Mucopolysaccharidoses

• α-L-Iduronidase (Hurler): corneal clouding, dysostosis multiplex, airway obstruction, cardiac valve thickening, developmental delay.
• Iduronate-2-sulfatase (Hunter): X-linked, no corneal clouding, aggressive/hyperactive behavior, milder trajectory.

• Cherry-red macula plus hepatosplenomegaly = Niemann-Pick A; cherry-red macula without organomegaly = Tay-Sachs. This single discriminator resolves most vignettes. Gaucher has no cherry-red spot.
• Match the cell to the disease: crumpled tissue paper macrophages = Gaucher; foam cells = Niemann-Pick; globoid cells = Krabbe; metachromatic granules = metachromatic leukodystrophy.
• Single best next step for suspected Gaucher: leukocyte β-glucocerebrosidase enzyme assay, not bone marrow biopsy. Marrow aspiration is the classic distractor — it shows Gaucher cells but is invasive and non-definitive.
• Hurler vs Hunter: corneal clouding and worse course = Hurler (autosomal recessive); clear cornea, aggressive behavior, X-linked = Hunter.
• Elevated plasma acid hydrolases in a coarse-featured infant with gingival hyperplasia points to I-cell disease — the defect is in M6P tagging, not in any one enzyme.
• Enzyme replacement therapy does not cross the blood-brain barrier. Predict benefit for visceral, hematologic, and skeletal disease (Gaucher type 1, Fabry, Pompe cardiomyopathy, MPS I/II somatic features) and no meaningful CNS benefit in neuronopathic forms; hematopoietic stem cell transplant is the CNS-directed option considered in presymptomatic Hurler and infantile Krabbe.
• Young adult with unexplained neuropathic burning of hands and feet, hypohidrosis, and proteinuria — think Fabry and test α-galactosidase A activity (males) or GLA sequencing (females, in whom enzyme activity can be normal).
• The one carrier-screening association: ACOG and ACMG recommend offering Tay-Sachs carrier screening to individuals of Ashkenazi Jewish ancestry, with expanded panels covering Gaucher and Niemann-Pick A; a normal enzyme assay does not exclude an activator protein deficiency.
• Distractor to avoid: a floppy infant with cardiomegaly is Pompe, not a mucopolysaccharidosis and not spinal muscular atrophy — check acid α-glucosidase.

• Lysosomal storage diseases result from deficiency of lysosomal enzymes → accumulation of undegraded substrates
• Autosomal recessive inheritance (except Hunter syndrome = X-linked recessive)
• Most present in infancy/early childhood with progressive neurodegeneration
• Diagnosis via enzyme assay, genetic testing, or substrate accumulation markers
• Prognosis generally poor; most are neurodegenerative with limited treatment options

"Child with developmental delay, hepatosplenomegaly, coarse facial features, and progressive neurodegeneration"

• Early milestones normal → gradual regression
• Macrocephaly, coarse facies, corneal clouding common
• Organomegaly (hepatosplenomegaly)
• Skeletal dysplasia, developmental regression

• Pompe confusion: Often grouped with glycogen storage diseases (autosomal recessive glycogenosis VII) but is lysosomal; unique for cardiac hypertrophy + hypotonia ("floppy baby")
• Gaucher Type 1 vs. CNS variants: Type 1 is non-neuropathic (good prognosis with enzyme replacement); Types 2 & 3 have CNS involvement
• Missdiagnosing presentation as primary neurologic disorder: Always consider metabolic/storage disease in progressive developmental regression with organomegaly